Introduction {#Sec1}
============

Drp1 (Dynamin-related protein) is an \~ 80-kDa protein (monomer) that is widely expressed in the brain, lung, heart, kidney, spleen, liver, hepatocytes, testis and fibroblasts in humans \[[@CR1], [@CR2]\]. Drp1 contains an N-terminal GTPase domain, a helical domain at the center and a GED (GTPase effector domain) at the C-terminus \[[@CR3]\]. In the cytoplasm, Drp1 exists as a dimer or tetramer and functions to induce the mitochondrial fission process \[[@CR4], [@CR5]\]. Mitochondria are organelles that are responsible for several vital cell functions, including respiration, oxidative phosphorylation, and regulation of apoptosis \[[@CR6]\]. The brain is an organ that requires a high energy level. In the brain, mitochondria move along cytoskeletal tracks to sites of high energy demand, such as synapses, and change their morphology by fusion and fission in response to cellular metabolic activity \[[@CR7]\]. Therefore, the balance of mitochondrial fission and fusion under the control of Drp1 is significant in maintaining brain function and energy supply \[[@CR8]\]. Drp1 overexpression or mutation can alter this balance. Mutant Drp1 causes mitochondria to collapse into perinuclear clusters that contain a highly interconnected network \[[@CR4], [@CR9]\]. Additionally, lack of Drp1 results in mitochondrial elongation and connection of mitochondrial tubules \[[@CR10]\]. These elongated mitochondria gradually accumulate oxidative damage and transform from elongated tubules into large spheres \[[@CR11]\]. Such changes will finally lead to nervous system diseases.

It has been confirmed that many diseases are related to Drp1 and mitochondria, including neurodegenerative diseases and neuropathic pain \[[@CR12]\]. Gao et al. have demonstrated that mitochondrial dysfunction is a common prominent early pathological feature in neurodegenerative diseases \[[@CR13]\]. A large number of studies have demonstrated that mitochondrial dysfunction is one of the best documented abnormalities and prominent early features in brain neurodegenerative diseases. Conversely, Guo et al. demonstrated that mitochondrial fission leads to an increase in ROS \[[@CR14]\], and the increase in ROS will further induce neuropathic and inflammatory pain \[[@CR15]\]. Ferrari et al. found that in models of chemotherapy-induced neuropathic pain, ROS greatly induces Drp1-dependent mitochondrial fission \[[@CR16]\]. To identify the target treatment strategy, some researchers have identified certain molecules as Drp1 inhibitors, including P110 and mdivi-1 \[[@CR16], [@CR17]\]. However, the impact of these molecules on the human body and their range of functions are still unclear.

In addition to neurodegenerative diseases and neuropathic pain, glioma is also correlated with Drp1-mediated changes in mitochondrial dynamics. Eugenio-Pérez et al. showed that Drp1 and mitochondrial dynamics are involved in the pluripotency maintenance of glioma stem cells. Additionally, Drp1 upregulation can support glioma cells to survive in circumstances far from the vasculature and lacking nutrients. Therefore, Eugenio-Pérez et al. raised the point that Drp1 and mitochondria contribute to gliomagenesis under cell homeostasis disorder \[[@CR18]\]. Nevertheless, from the aspect of glioma treatment and prognosis, it remains to be determined whether there is a correlation between the glioma grade and Drp1 expression changes. Moreover, antineoplastic drug development of Drp1 also requires information on the Drp1 distribution and level changes.

Currently, the Drp1 subcellular distribution between cytoplasm and mitochondria has been observed in HeLa cell lines in several investigations \[[@CR19]\]. Despite prior knowledge that Drp1 is widely expressed in organs such as the brain from the macro perspective, the exact distribution of Drp1 in different neuronal compartments or even in the central nervous system is still lacking experimental evidence \[[@CR1], [@CR19]\]. Thus, an understanding of the exact distribution of Drp1 in the central nervous system is urgently required. Clarifying the specific Drp1 distribution and Drp1 expression changes in glioma could be a good approach to the targeted treatment or prognosis for diseases.

In this study, we investigated the specific distribution of Drp1 in neurons, GABAergic (γ-aminobutyric acid) neurons and mitochondria under an optical microscope and TEM (transmission electron microscope). We also explored the changes in expression of Drp1 in grade I-IV human malignant glioma. Taking together the above results, we conclude that Drp1 is widely but heterogeneously distributed in the central nervous system, and this heterogeneous distribution may contribute to the occurrence and development of neurologic diseases. We hope that this research may provide novel insights into targeted treatment of disease in the clinic.

Results {#Sec2}
=======

Drp1 is widely distributed in the central nervous system {#Sec3}
--------------------------------------------------------

To explore the specific distribution of Drp1 in the mouse CNS (central nervous system), we observed its expression in different mouse brain regions and the spinal cord.

At the protein level {#Sec4}
--------------------

To preliminarily explore a potential regional distribution of Drp1 protein, western blot was used to detect the protein in the cortex, hippocampal region, cerebellum, medulla, thalamus and spinal cord. The results showed differences in Drp1 at the protein level in six regions, with the highest expression in the spinal cord and lowest expression in the cortex, hippocampal region and cerebellum (*p* \< 0.05) (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Drp1 protein content in the brain and spinal cord. **a**. Western blot results for the cortex, hippocampal region, cerebellum, medulla, thalamus and spinal cord. **b**. Relative density of Drp1. ImageJ software was used to calculate the gray value of each band, the ratio of the gray value of Drp1/β-actin was calculated, and one-way ANOVA was used for statistical analysis. The results showed no significant difference in the expression of Drp1 in the six regions (*p* \> 0.05). Thus, we further utilized LSD (least significant difference) to compare each group. The expression of Drp1 was higher in the spinal cord than in the cerebral cortex, hippocampal region, cerebellum and medulla (*p* = 0.043, 0.046, 0.009, 0.028, respectively); however, there was no difference in the expression of Drp1 among different brain nuclei (*p* \> 0.05). \* *p* \< 0.05

We next explored the exact expression of Drp1 utilizing immunofluorescence staining. Drp1 expression was determined based on the labeling intensity, which was classified as no signal (−), low signal (+), moderate signal (++), high signal (+++), and strong signal (++++) \[[@CR20]\].

The results showed that Drp1 was expressed in layer 5 and 6a of the cerebral cortex, and some expression was also observed in layer 2, although we did not detect obvious Drp1 expression in layer 1 (Fig. [2](#Fig2){ref-type="fig"} a). Drp1 was poorly expressed in the hippocampal region. However, some neurons in the DG-po (polymorphic layer of dentate gyrus) and CA1so (field CA1, stratum oriens) displayed Drp1 expression in the soma and neurite (Fig. [2](#Fig2){ref-type="fig"} c, d). In the cerebellum, Drp1 protein expression was mainly concentrated in the SIMpu (simple lobule, Purkinje layer). Drp1-positive cells in pu were arranged in a single layer, separating the mo (molecular layer) and the gr (granular layer) (Fig. [2](#Fig2){ref-type="fig"} b). In the spinal cord, high Drp1 expression was observed in the deep layers (VII, VIII, IX, X), which was slightly higher than that in the superficial layers (I, II, III) (Fig. [2](#Fig2){ref-type="fig"} e, f). Fig. 2Drp1 protein distribution in the cerebral cortex, cerebellum, hippocampal region and spinal cord. **a**. The distribution of Drp1 in the cerebral cortex. Drp1 was barely expressed in the first layer of the CTX, and specific staining results were obtained in the second/third layer. Compared with the other layers, Drp1 expression was higher in the fifth layer than the others. **b**. The distribution of Drp1 in the cerebellum. Drp1 was expressed in the cytoplasm around the nucleus (DAPI). In addition, Drp1-positive protuberant structures were also found in the mo region, which were long strips and, possibly, axons. **c**. The distribution of Drp1 in the hippocampal region. The distribution of Drp1 (green) and DAPI (blue) in the CA1 and DG regions. Drp1 was expressed at low levels in CA1, DG-mo and DG-sg. Drp1 was highly expressed in DG-po. **d**. The magnified image of C. From D, we can see that some Drp1-positive cells in DG-mo and DG-po regions had a protuberance around them, which might represent axons or dendrites. **e**. Drp1 distribution in the spinal cord. **e** provides a complete view of the spinal cord. In the deep layers (VII, VIII, IX, X), Drp1 expression was slightly higher than in the superficial layers (I, II, III). **f**. In the spinal dorsal horn, Drp1 was weakly expressed. Bar = 200 μm **a, c, e**; 100 μm **d, f**; 30 μm **b**. Abbreviations: CTX: cerebral cortex; cing: cingulum bundle; SIMpu: simple lobule, Purkinje cell; SIMmo: simple lobule, molecular layer; SIMgr: simple lobule, granular layer; cc: corpus callosum; CA: Ammon's horn; CA1-so: field CA1, stratum oriens; CA1-sp: field CA1, pyramidal layer; CA1-sr: field CA1, stratum radiatum; CA1-slm: field CA1, stratum lacunosum-moleculare; DG-mo: molecule layer of dentate gyrus; DG-sg: granular cell layer of dentate gyrus; DG-po: polymorphic layer of dentate gyrus

Among all the regions, we selected four regions in which Drp1 was highly expressed (Fig. [3](#Fig3){ref-type="fig"}). In the thalamus, Drp1 was highly expressed in the LGd (dorsal part of the lateral geniculate complex) and LGv (ventral part of the lateral geniculate complex) (Fig. [3](#Fig3){ref-type="fig"} a). In the pons, Drp1 expression was higher in the PB (parabrachial nucleus), LC (locus ceruleus) and B (Barrington's nucleus) than in other nuclei (Fig. [3](#Fig3){ref-type="fig"} b). The labeling intensity in the CN (cochlear nuclei) and VII (facial motor nucleus) achieved a strong signal (++++) (Fig. [3](#Fig3){ref-type="fig"} c d). Details of expression of Drp1 protein in all regions are shown in Table [1](#Tab1){ref-type="table"}. Moreover, based on the *Allen Mouse Brain Atlas* \[[@CR21]\], we also analyzed the proportion of different Drp1 protein labeling intensities in the brain and spinal cord. The right part of the figure exhibited Drp1 protein expression (Fig. [5](#Fig5){ref-type="fig"}), with a low signal (+) accounting for the majority (59% in brain, 60% in spinal cord). Fig. 3Brain regions with high Drp1 protein expression. Drp1 was highly expressed in LGd and LGv **a**, PB **b**, CN **c** and VII **d**. C1 and D1 show magnified images of C and D. Bar = 100 μm **a, b**; 200 μm **c, d**; 30 μm (C1, D1). Abbreviations: LGd: dorsal part of the lateral geniculate complex; LGv: ventral part of the lateral geniculate complex; IGL: intergeniculate leaflet of the lateral geniculate complex; MGv: medial geniculate complex, ventral part; PB: parabrachial nucleus; B: Barrington's nucleus; LC: locus ceruleus; MEV: midbrain trigeminal nucleus; SUV: superior vestibular nucleus; CN: cochlear nuclei; VII: facial motor nucleusTable 1Drp1 protein and mRNA expression in different brain regions and spinal cordAbbreviationRegionsIntensityproteinmRNA**CTXcerebral cortex** RSPv1retrosplenial area, ventral part, layer 1**--**+ RSPv2/3retrosplenial area, ventral part, layer 2/3**+**++++ RSPv5retrosplenial area, ventral part, layer 5**++**+++ RSPv6retrosplenial area, ventral part, layer 6**+**+++ RSPd1retrosplenial area, dorsal part, layer 1**--**+ RSPd2/3retrosplenial area, dorsal part, layer 2/3**+**+++ RSPd5retrosplenial area, dorsal part, layer 5**++**+++ RSPd6retrosplenial area, dorsal part, layer 6**+**+++ PTLp1posterior parietal association areas, layer 1**--**+ PTLp2/3posterior parietal association areas, layer 2/3**+**+++ PTLp4posterior parietal association areas, layer 4**+**+++ PTLp5posterior parietal association areas, layer 5**++**+++ PTLp6posterior parietal association areas, layer 6**+**+++ AUD1auditory area, layer 1**--**+ AUD2/3auditory area, layer 2/3**+**++++ AUD4auditory area, layer 4**+**+++ AUD5auditory area, layer 5**++**+++ AUD6auditory area, layer 6**+**+++ TEa1temporal association areas, layer 1**--**+ TEa2/3temporal association areas, layer 2/3**+**++++ TEa4temporal association areas, layer 4**+**+++ TEa5temporal association areas, layer 5**++**+++ TEa6temporal association areas, layer 6**+**+++ PIR1piriform area, molecular layer 1**--**+ PIR2piriform area, molecular layer 2**+**++++ PIR3piriform area, polymorph layer 3**+**++**HIPhippocampal region** CA1sofield CA1, stratum oriens++ CA1spfield CA1, pyramidal layer+++++ CA1srfield CA1, stratum radiatum++ CA1slmfield CA1, stratum lacunosum-moleculare+++ DG-momolecule layer of dentate gyrus++ DG-sggranular cell layer of dentate gyrus+++++ DG-popolymorphic layer of dentate gyrus+++++**THthalamus** VPLventral posterolateral nucleus of the thalamus**+**+++ VPMventral posteromedial nucleus of the thalamus**+**+++ LGddorsal part of the lateral geniculate complex**+++**+++ IGLintergeniculate leaflet of the lateral geniculate complex**++**+++ LGvventral part of the lateral geniculate complex**+++**+++ POposterior complex of the thalamus**+**+++ PFparafascicular nucleusN/A+++**MBmidbrain** PAGperiaqueductal gray+++++ MRNmidbrain reticular nucleusN/A++ ICinferior colliculusN/A+++ DRdorsal nucleus rapheN/A++++**Ppons** PBparabrachial nucleus++++++++ LClocus ceruleus+++++++ BBarrington's nucleus+++++++ PCGpontine central gray++++**MYmedulla** CNcochlear nuclei+++++++ VCOventral cochlear nucleus+++++++ DCOdorsal cochlear nucleus+++++++ CNlamgranular lamina of the cochlear nuclei++++++ PARNparvicellular reticular nucleus+++ VIIfacial motor nucleus+++++++ SPVIspinal nucleus of the trigeminal, interpolar part+++N/A NTSnucleus of solitary tract++N/A ECUexternal cuneate nucleus++++N/A PASparasolitary nucleus+N/A MDRNmedullary reticular nucleus+++N/A SPVOspinal nucleus of the trigeminal, oral partN/A++ IRNintermediate reticular nucleusN/A++ sptVspinal tract of the trigeminal nerveN/A+ SPIVspinal vestibular nucleus++N/A**CBcerebellum** SIMgrsimple lobule, granular layer--++++ SIMpusimple lobule, Purkinje layer++++++++ SIMmosimple lobule, molecular layer+++ FLgrflocculus, granular layer--++++ FLmoflocculus, molecular layer+++ IPinterposed nucleus+++++ SUVsuperior vestibular nucleusN/AN/A MGvmedial geniculate complex, ventral partN/AN/A MEVmidbrain trigeminal nucleusN/AN/A**fiber tracts** cingcingulum bundle**--**+ cccorpus callosum**--**+ alvalveus--+ dfdorsal fornix--+ frfasciculus retroflexusN/A+ scpsuperior cerebelar pedunclesN/A+ icpinferior cerebellar peduncleN/A+ sctvventral spinocerebellar tractN/A+ rustrubrospinal tractN/A+**VSventricular systems** V4fourth ventricleN/A-- V4rlateral recessN/A++++ AQcerebral aqueductN/A--**spinal cord** Lamina I+++++ Lamina II++++ Lamina III++++ Lamina IV++++ Lamina V++++ Lamina VI++++ Lamina VII+++++ Lamina VIII+++++ Lamina IX+++++ Lamina X+++++Drp1 expression was determined based on the labeling intensity, which was classified as no signal (−), low signal (+), moderate signal (++), high signal (+++), and strong signal (++++). "N/A" represents this region was not observed or counted

In conclusion, Drp1 protein is widely distributed in the brain and spinal cord, confirming the importance of Drp1 in the CNS.

At the mRNA level {#Sec5}
-----------------

### Probe titer determination {#Sec6}

Using the correctly sequenced recombinant plasmid as the template, the sequence containing the target gene fragment and SP6/T7 promoter joints at both ends was amplified. After amplification, we determined the probe concentration. The Drp1 probe carrying SP6 and T7 was 281.27 ng/μl and 202.61 ng/μl, respectively.

### Identification of probes and antisense probes {#Sec7}

Drp1 mRNA gene probes included the upstream and downstream promoter SP6 and T7 sequences, while the sense sequence probes served as the negative control. The results showed a high hybridization signal of SP6 probe, and specific punctate granules were observed, while the T7 probe showed no specific staining. Therefore, the antisense sequence of the target gene Drp1 with SP6 as the promoter was selected for subsequent experiments.

### A wide distribution of Drp1 mRNA in the mouse brain and spinal cord {#Sec8}

Results showed that Drp1 mRNA was widely distributed in all mouse brain regions with a strong hybridization signal and high specificity (Fig. [4](#Fig4){ref-type="fig"} a). Fig. 4Drp1 mRNA distribution in the whole brain and spinal cord. **a**. mRNA distribution of Drp1 in the brain. The section refers to *The Allen Mouse Brain Atlas* (Mouse, P56, Coronal, image 72 of 132). **b**. mRNA distribution of Drp1 in the spinal cord. Drp1 mRNA was highly expressed in all layers (I-X). The mRNA expression of Drp1 was higher in layer I than in the other layers. **c-n**. Nuclei with high Drp1 mRNA expression. In the cerebral cortex, Drp1 was highly expressed in RSP **c**, AUD **d**, and PIR **e**. In the hippocampal region, Drp1 was highly expressed in CA1sp, DG-sg **f**. In the thalamus, Drp1 was highly expressed in PF **g**, LGv, LGd **h**, In the midbrain, Drp1 was highly expressed in IC **i**, PAG, DR **j**. In the pons, Drp1 was highly expressed in PB, LC, B, PCG **k**. In the medulla, Drp1 was highly expressed in PARN, IRN, VII **l**, VCO, DCO **m**. In the cerebellum, Drp1 was highly expressed in SIMgr **n**. Bar = 1 mm **a**; 200 μm **b-n**. Abbreviations: RSPd: retrosplenial area, dorsal part; RSPv: retrosplenial area, ventral part; PTLp: posterior parietal association areas; cc: corpus callosum; cing: cingulum bundle; AUD: auditory areas; TEa: temporal association areas; BLA: basolateral amygdalar nucleus; PIR: piriform area; alv: alveus; df: dorsal fornix; cc: corpus callosum; CA: ammom's horn; CA1-so: field CA1, stratum oriens; CA1-sp: field CA1, pyramidal layer; CA1-sr: field CA1, stratum radiatum; CA1-slm: field CA1, stratum lacunosum-moleculare; DG-mo: molecule layer of dentate gyrus; DG-sg: granular cell layer of dentate gyrus; DG-po: polymorphic layer of dentate gyrus; PO: posterior complex of the thalamus; VPM: ventral posteromedial nucleus of the thalamus; VPL: ventral posterolateral nucleus of the thalamus; LGd: dorsal part of the lateral geniculate complex; LGv: ventral part of the lateral geniculate complex; IGL: intergeniculate leaflet of the lateral geniculate complex; fr: fasciculus retroflexus; PF: parafascicular nucleus; IC: inferior colliculus; PAG: periaqueductal gray; AQ: cerebral aqueduct; DR: dorsal nucleus raphe; MRN: midbrain reticular nucleus; V4: fourth ventricle; PB: parabrachial nucleus; B: Barrington's nucleus; LC: locus ceruleus; PCG: pontine central gray; scp: superior cerebelar peduncles; SIMmo: simple lobule, molecular layer; SIMgr: simple lobule, granular layer; V4r: lateral recess; icp: inferior cerebellar peduncle; FL: flocculus; SPVO: spinal nucleus of the trigeminal, oral part; sptV: spinal tract of the trigeminal nerve; VCO: ventral cochlear nucleus; DCO: dorsal cochlear nucleus; IRN: intermediate reticular nucleus; PARN: parvicellular reticular nucleus; sctv: ventral spinocerebellar tract; rust: rubrospinal tract

Considering all the results, four regions were selected for further description. In the thalamus, Drp1 was highly expressed in the LGd, LGv and IGL (intergeniculate leaflet of the lateral geniculate complex), with the fluorescence intensity of these three nuclei reaching a high signal (+++) (Fig. [4](#Fig4){ref-type="fig"} h). In the pons, the expression of Drp1 mRNA reached a strong signal (++++) in the PB, LC and B. Expression was lower in the PCG (pontine central gray) than that in these nuclei (Fig. [4](#Fig4){ref-type="fig"} k). In the medulla, Drp1 mRNA was highly expressed in the VCO (ventral cochlear nucleus) and DCO (dorsal cochlear nucleus) (Fig. [4](#Fig4){ref-type="fig"} m). Drp1 mRNA was also widely distributed in the mouse spinal cord, demonstrating a strong hybridization signal (Fig. [4](#Fig4){ref-type="fig"} b). Details of the Drp1 mRNA expression in other regions are shown in Table [1](#Tab1){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}.

Moreover, we compared the Drp1 labeling intensity at the protein and mRNA levels. Based on the *Allen Mouse Brain Atlas* \[[@CR21]\], the Drp1 signal was visualized in different brain slices. The left part of the figure showed Drp1 mRNA expression, and the right part showed Drp1 protein expression. The results showed that a high intensity Drp1 mRNA labeling signal (+++) accounted for the majority of the expression (53% in brain, 90% in spinal cord), which was higher than the same protein level (+++) in both the brain (10%) and spinal cord (0%) (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Comparison of Drp1 mRNA and protein expression. **a**. Comparison of Drp1 mRNA and protein expression in the brain. Based on the *Allen Mouse Brain Atlas*, the Drp1 signal was visualized in four different brain coronal sections. The left part shows the Drp1 mRNA expression, and the right part shows the Drp1 protein expression. **b**. Comparison of Drp1 mRNA and protein expression in the spinal cord. Drp1 mRNA was highly expressed in layer I; in the deep layers (VII, VIII, IX, X), Drp1 protein expression was slightly higher than in the superficial layers (I, II, III). **c**. Statistical analysis of the Drp1 mRNA and protein expression comparison in the brain. Drp1 expression was determined based on the labeling intensity, which was classified as no signal (−), low signal (+), moderate signal (++), high signal (+++), and strong signal (++++). The expression levels of Drp1 mRNA and protein were statistically analyzed based on 148 mice brain nuclei. The results showed that the Drp1 mRNA and protein expression levels were different in the mouse brain. In the brain, high expression of Drp1 mRNA ("+ + +" accounting for 53%) but low expression of Drp1 protein was mostly observed ("+" accounting for 59%). D. Statistical analysis of Drp1 mRNA and protein expression comparison in the spinal cord. In the spinal cord, high expression of Drp1 mRNA ("+ + +" accounting for 90%) but low expression of Drp1 protein was mostly observed ("+" accounting for 60%)

In conclusion, Drp1 was widely distributed in the central nervous system but with heterogeneity, with some areas or nuclei showing high Drp1 expression. Heterogeneity was also found between the Drp1 mRNA and protein level.

Mainly and highly expressed Drp1 in neurons {#Sec9}
-------------------------------------------

The localization of Drp1 in the brain and spinal cord was consistent with what has been proposed in the traditional theory that Drp1 is widely distributed in the CNS \[[@CR1]\]. However, unequivocal proof of the innervation is still lacking.

To specify the Drp1 distribution in neurons, we utilized double immunofluorescence to label Drp1 and neurons with the anti-Drp1 antibody and anti-NeuN (neuronal nuclear antigen) antibody. Considering all the results, two representative nuclei were selected, and we found that the fluorescence of Drp1 (green) and NeuN (red) coincided well in the VII (Fig. [6](#Fig6){ref-type="fig"} a). However, Drp1 and NeuN were colabeled only in a few parts of the CN, but in other areas of the CN with Drp1 expression, NeuN staining was not found (Fig. [6](#Fig6){ref-type="fig"} b). Fig. 6Colabeling of Drp1 and NeuN. **a**. Drp1 and NeuN staining results in VII. In this nucleus, Drp1 and NeuN were completely colabeled. **b**. Drp1 and NeuN staining results in the CN. Drp1 and NeuN were colabeled only in a few parts. In other areas of the CN expressing Drp1, however, NeuN staining was not detected. Bar = 100 μm **a, b**. Abbreviations: CN: cochlear nuclei; VII: facial motor nucleus; NeuN: neuronal nuclear antigen

In conclusion, Drp1 is mainly and highly expressed in neurons in the central nervous system, and in parts of the nervous system other than neurons, low levels of Drp1 expression could also be observed.

Highly expression of Drp1 in GABAergic neurons {#Sec10}
----------------------------------------------

GABAergic neurons are important inhibitory neurons, which is correlated with the development of many neurological diseases, including Huntington's disease, Alzheimer's disease, anxiety, panic disorder and epilepsy \[[@CR22]--[@CR24]\]. To explore the effect of Drp1 on these diseases, we further clarified the distribution of Drp1 in GABAergic neurons (Fig. [7](#Fig7){ref-type="fig"} a). GAD67 (glutamic acid decarboxylase 67)-GFP (green fluorescent protein) transgenic mice were utilized for further observation. In GAD67-GFP transgenic mice, GABAergic neurons are specifically labeled with GFP fluorescence, which will induce spontaneous neuronal fluorescence under a confocal microscope \[[@CR25]--[@CR27]\]. Therefore, colabeling of GABAergic neurons and Drp1 in different brain regions could be observed by GFP and red fluorescence (anti-Drp1 antibody). Fig. 7Colabeling of Drp1 and GAD67. **a**. The heterogeneous distribution of Drp1 in different kinds of neurons was further observed. GAD67-GFP transgenic mice were used to observe the colabeling of GABAergic neurons and Drp1 in different brain regions. **b**. Drp1 and GAD67 were double-labeled in SIMpu. The pu cells expressed Drp1 and GAD67, demonstrating complete colabeling. **c**. Drp1 and GAD67 in the medulla. Drp1 was highly expressed in SPVI and weakly expressed in MDRNd, while GAD67 showed lower expression in SPVI and higher expression in MDRNd. **d**. Drp1 and GAD67 in ECU. The results showed that Drp1 and GAD67 were not colabeled in most of this area. Bar = 100 μm (A-C); 25 μm (A1-C1). Abbreviations: GAD67: glutamic acid decarboxylase 67; GABA: γ-Aminobutyric acid; SIMpu: simple lobule, Purkinje layer; SIMmo: simple lobule, molecular layer; SIMgr: simple lobule, granular layer; MDRNd: medullary reticular nucleus, dorsal part; SPVI: spinal nucleus of the trigeminal, interpolar part; ECU: external cuneate nucleus; NTS: nucleus of solitary tract; PAS: parasolitary nucleus

We selected three Drp1 and GAD67 double-stained nuclei, including SIMpu, SPVI (spinal nucleus of the trigeminal, interpolar part), and ECU (external cuneate nucleus). The results indicated that Drp1 was overexpressed in the cerebellum Purkinje layer, while Drp1 and GAD67 also colabeled well in this area. Drp1 and GAD67 colabeling was lower in other nuclei (Fig. [7](#Fig7){ref-type="fig"}).

Drp1 was localized not only in mitochondria, but mostly in cytoplasm and dendrites {#Sec11}
----------------------------------------------------------------------------------

As we discussed above, the relationship of Drp1 and mitochondria to many neurologic diseases has been confirmed \[[@CR2]\]. Moreover, Drp1 is significant in maintaining mitochondrial function through the balanced control of mitochondrial fission and fusion \[[@CR8]\]. Therefore, we observed the localization of mitochondrial Drp1 in the brain nucleus. Double labeling of Drp1 (green) and Mito-Red (red) in the LGd, SPIV (spinal vestibular nucleus) and IP (interposed nucleus) showed that Mito-Red completely colocalized with Drp1, while in contrast, the range of the Drp1 distribution was wider than the Mito-Red. Both Drp1 and Mito-Red were scattered around the nucleus. Mito-Red was concentrated on one side of the cell nucleus, while Drp1 expression showed no polarity and connected to form a network structure around the nucleus. In conclusion, the size of the green (Drp1) granules was smaller than the red (Mito-Red) one, but the distribution range of Drp1 was wider than Mito-Red, indicating that Drp1 was localized not only to mitochondria, but mostly in other regions (Fig. [8](#Fig8){ref-type="fig"}). Considering that the fluorescent particles may overlap in vertical space, we utilized an electron microscope for further observations (Fig. [9](#Fig9){ref-type="fig"} a). Fig. 8Distributions of Drp1 and Mito-Red in the brain nucleus. **a**. Drp1, Mito-Red and DAPI in the dorsal part of the LGd. Drp1 and Mito were scattered around the nucleus. **b**. Drp1, Mito and DAPI in SPIV. **c**. Drp1, Mito and DAPI in the IP. **d**. Ratio of the Mito/Drp1 fluorescence area. Ten neurons were selected for further analysis. ImageJ software was utilized to calculate the area of Mito-Red and Drp1 fluorescence in each cell. The results showed that the ratio fluctuated around 0.3. Bar = 10 μm. Abbreviations: Drp1: Dynamin-related protein 1; LGd: dorsal part of the lateral geniculate complex; SPIV: spinal vestibular nucleus; IP: interposed nucleusFig. 9Drp1 distribution under TEM. **a**. Considering that the fluorescent particles might overlap in vertical space, the distribution of mitochondrial Drp1 in the PAG brain was further observed at the subcellular level under an electron microscope. **b**. The distribution of Drp1 under TEM. The black particulate matter is colloidal gold particles, which represent Drp1-positive expression (red arrows). Brown represents the axon (A), blue represents the axon terminal (AT), red represents dendrites (D), and green represents the soma (S). Bar =500 nm. **c**. Quantity of Drp1 in the axon, axon terminal, dendrites and soma. The Kruskal-Wallis test results showed that the quantity of Drp1 was significantly different in four regions (*p* \< 0.001). The quantity of Drp1 was higher in dendrites than axons (*p* \< 0.001) and axon terminals (*p* \< 0.001). The quantity of Drp1 was higher in soma than axons (*p* \< 0.001) and axon terminals (*p* \< 0.001). **d**. The ratio of Drp1 expression per unit area. Kruskal Wallis test results showed that ratio of Drp1 expression per unit area was significantly different in four regions (*p* \< 0.001). The ratio was larger in dendrites than axons (*p* \< 0.001) and axon terminals (*p* \< 0.001). **e**. Quantity of mitochondria in the axon, axon terminal, dendrites and soma. Using an independent-sample Kruskal-Wallis test for analysis, the results showed that the quantity of mitochondria was significantly different in four regions (*p* \< 0.001). Pairwise comparisons indicated that the quantity of mitochondria was greater in dendrites than axons (*p* \< 0.001) and axon terminals (*p* = 0.001). The quantity of mitochondria was greater in soma than axons (*p* \< 0.001) and axon terminals (*p* \< 0.001). **f**. Proportion of Drp1 in mitochondria/total Drp1 in every region and mitochondria with Drp1/total mitochondria in every region. The proportion of Drp1 in mitochondria/total Drp1 in every region was quantified. The results showed that in dendrites, 4.72% of the Drp1 was localized to mitochondria (maximum), while in axons this proportion was only 2.5% (minimum). Similarly, the proportion of mitochondria with Drp1/total mitochondria in every region was also calculated. The results showed that in dendrites, 30.34% of the mitochondria localized with Drp1 (maximum), and this was proportion only 14.82% in axonal terminals (minimum). \* *p* \< 0.05, \*\* *p* \< 0.01. Abbreviations: TEM: transmission electron microscope; PAG: periaqueductal gray

Next, we investigated the distribution of mitochondrial Drp1 in the PAG (periaqueductal gray) at the subcellular level under an electron microscope. The immune colloidal gold technique was utilized to label Drp1. Colloidal gold was the tracer, which could combine with the positively charged protein molecules in the weak alkaline environment \[[@CR28], [@CR29]\]. In Fig. [9](#Fig9){ref-type="fig"}, the black particulate matter is colloidal gold particles, which represent positive Drp1 expression (red arrows). The results showed that Drp1 was mainly expressed in the cytoplasmic matrix, which was consistent with our above results. Dendrites could also exhibit some expression, and a small amount of punctate Drp1 expression was distributed on the mitochondrial membrane (Fig. [9](#Fig9){ref-type="fig"} b).

We then further investigated the quantity of mitochondria and Drp1 in axons, axon terminals, dendrites and soma. Seventy axons, 37 axon terminals, 36 dendrites and 6 somas were counted, and the average quantity of mitochondria and Drp1 in each part was calculated. Utilizing the Kruskal-Wallis test, we analyzed Drp1 expression and its correlation with mitochondria from four aspects (Fig. [9](#Fig9){ref-type="fig"} c-f): A)Quantity of Drp1

The quantity of Drp1 was significantly different in four regions (*p* \< 0.001). The quantity of Drp1 was greater in dendrites than axons (*p* \< 0.001) and axon terminals (*p* \< 0.001). The quantity of Drp1 was greater in soma than axons (*p* \< 0.001) and axon terminals (*p* \< 0.001) B)Ratio of Drp1 expression per unit area

The ratio of Drp1 expression per unit area was significantly different in four regions (*p* \< 0.001). The ratio was larger in dendrites than axons (*p*\<0.001) and axon terminals (*p*\<0.001). C)Quantity of mitochondria

The results indicated that the quantity of mitochondria was significantly different in four regions (*p* \< 0.001). The quantity of mitochondria was greater in dendrites than axons (*p* \< 0.001) and axon terminals (*p* = 0.001). The quantity of mitochondria was greater in soma than axons (*p* \< 0.001) and axon terminals (*p* \< 0.001). D)Proportion of Drp1 on mitochondria/total Drp1 in every region and mitochondria with Drp1/total mitochondria in every region

The proportion of Drp1 on mitochondria/total Drp1 in every region was counted. The results showed that in dendrites, 4.72% of the Drp1 was localized to mitochondria (maximum), while in axons this proportion was only 2.5% (minimum).

Similarly, the proportion of mitochondria with Drp1/total mitochondria in every region was also calculated. The results showed that in dendrites, 30.34% mitochondria were localized to Drp1 (maximum), and this proportion was only 14.82% in axonal terminals (minimum). \**p* \< 0.05, \*\**p* \< 0.01.

Drp1 expression in human malignant glioma tissue reached the highest value in grade III and then declined {#Sec12}
---------------------------------------------------------------------------------------------------------

As stated above, in components other than neurons, Fig. [6](#Fig6){ref-type="fig"} also showed a low level of Drp1 expression. Glial cells represent another kind of vital component in the brain other than neurons, and some previous research has demonstrated a relationship between Drp1 and glial cells. In models of ischemic injury, Zhou et al. demonstrated an upregulation of Drp1 and enhanced mitochondrial fission in microglia \[[@CR30]\]. Chae et al. revealed that Drp1-mediated mitochondrial fission could activate microglial cells by regulating p62-mediated autophagy \[[@CR31]\]. Considering the crucial role of Drp1 in glial cells, we speculated that the other regions expressing Drp1 were probably glial cells.

Therefore, we also analyzed Drp1 expression in human malignant glioma tissue. With the normal human brain as the control tissue, grade I represented juvenile glioma tissue and grade II-IV represented glioma tissue with mild, moderate and severe malignancy, respectively.

Eight fluorescent spots were randomly selected in every tissue grade. The Drp1 fluorescence intensity was calculated using ImageJ software (Table [2](#Tab2){ref-type="table"} & Fig. [10](#Fig10){ref-type="fig"}). One-way ANOVA was used for the statistical analysis. The results revealed significantly different Drp1 expression in glioma grade I-IV (*p* = 0.01). After the LSD (least significant difference) test, Drp1 expression was higher in the control group than grade I (*p* = 0.018). In contrast, it was higher in grade III than the control group (*p* = 0.036), grade I (*p* \< 0.001), grade II (*p* = 0.011), and grade IV (*p* = 0.001). \* *p* \< 0.05, \*\* *p* \< 0.01. Table 2Value of Drp1 fluorescence intensity in different glioma gradesControlgrade Igrade IIgrade IIIgrade IV**1**0.490.1340.2730.3260.254**2**0.4330.2320.3620.6180.273**3**0.5380.4540.2670.90.364**4**0.540.3140.5390.5560.508**5**0.450.180.7730.5850.67**6**0.2690.190.2450.2520.332**7**0.5130.1730.3810.6570.339**8**0.3350.2340.4021.1390.316**Mean value**0.4460.2390.4050.6290.382Eight fluorescent spots were randomly selected in every grade. Value of Drp1 fluorescence intensity was calculated by ImageJ software. One-way ANOVA was used for statistical analysis Results showed that Drp1 expression was significantly different in glioma I-IV grade (*p* = 0.01). After LSD test, Drp1 expression in control group was higher than that in grade I (*p* = 0.018). On the contrary, grade III was higher than that in control group (*p* = 0.036), grade I (*p* \< 0.001), grade II (*p* = 0.011), and grade IV (*p* = 0.001)Fig. 10Drp1 expression in human malignant glioma tissue. **a, b**. Drp1 immunofluorescence staining and HE staining of the same area in control tissue and human malignant glioma tissue grade I-IV. **c**. Comparison of the Drp1 fluorescence intensity in tissues of different grades. Eight fluorescent spots were randomly selected for every grade. The Drp1 fluorescence intensity was calculated using ImageJ software. One-way ANOVA was used for statistical analysis. The results showed that Drp1 expression was significantly different in glioma I-IV grade (*p* = 0.01). After the LSD test, Drp1 expression was higher in the control group than grade I (*p* = 0.018). In contrast, it was higher in grade III than the control group (*p* = 0.036), grade I (*p* \< 0.001), grade II (*p* = 0.011), and grade IV (*p* = 0.001). **d**. The mean Drp1 fluorescence intensity was calculated for every grade. From grade I-III, the mean Drp1 fluorescence intensity showed an increasing trend. In grade IV, the mean Drp1 fluorescence intensity was significantly reduced. \* *p* \< 0.05, \*\* *p* \< 0.01. Abbreviations: LSD: least significant difference

In conclusion, from grade I-III, the mean Drp1 fluorescence intensity showed an increasing trend. The mean Drp1 fluorescence intensity was significantly reduced in grade IV (Fig. [10](#Fig10){ref-type="fig"} c, d).

Discussion {#Sec13}
==========

The present study revealed a wide distribution of Drp1 in the central nervous system at both the protein and mRNA level, confirming the importance of Drp1. Moreover, Drp1 was widely expressed in the cytoplasm but barely in mitochondria, which is consistent with previous studies \[[@CR1], [@CR2]\]. However, the distribution of Drp1 also showed heterogeneity. Based on the heterogeneous distribution of Drp1, we discuss four possibilities underlying this phenomenon.

The heterogeneous distribution of Drp1 in dendrites provides the basic requirements for dendrite formation {#Sec14}
----------------------------------------------------------------------------------------------------------

All the immunofluorescence results showed the wide expression and distribution of Drp1 around the cell nucleus. In addition, we found that Drp1-positive protuberant structures (long strips in Fig. [2](#Fig2){ref-type="fig"} b) were potentially axons or dendrites. The IEM (immunoelectron microscopy) results further revealed that Drp1 was mainly expressed in the cytoplasmic matrix, while dendrites also showed some expression. Kruskal-Wallis analysis confirmed the heterogeneous distribution of Drp1 in different neuronal compartments. Together with the IEM and Kruskal-Wallis analysis results, we concluded that the amount of Drp1 was greater in the soma and dendrites than axons and axon terminals. Interestingly, the number of mitochondria showed the same characteristics. Moreover, the highest ratio of dendrites (Drp1 in mitochondria/total Drp1 in every region, mitochondria with Drp1/total mitochondria in every region) also indicated that Drp1 and its related mitochondrial dynamics played a vital role in this compartment.

The heterogeneous distribution of Drp1 in dendrites was probably indicative of its role in dendrite formation. By utilizing shRNAs to knockout Drp1, Itoh et al. revealed the crucial role of Drp1 in controlling primary dendrite formation in neurons. First, they demonstrated an enrichment of Drp1 in postsynaptic terminals (the majority is dendrite), which was consistent with our research. Second, in cultured neurons, they found that the loss of Drp1 induced ectopic dendrite extension, further affecting brain function \[[@CR32]\]. In addition, during the process of controlling dendrite formation, Drp1 was correlated with the mitochondrial distribution. Using molecular manipulations to inhibit Drp1 expression, Li and colleagues observed a decline in dendritic mitochondria, leading to the loss of dendritic spines \[[@CR33]\]. Moreover, in a mutant Drp1 fruit fly model, Verstreken et al. also revealed the absence of mitochondria in neuron postsynaptic terminals \[[@CR34]\]. Our electron microscopy calculations showed that the quantity of mitochondria was significantly different in four regions, with a larger amount in in dendrites than other compartments, confirming the abovementioned correlation between dendritic Drp1 and mitochondria. Therefore, the heterogeneous distribution of Drp1 in dendrites further indicated its vital role in normal neuronal function, and provided the basic requirement for dendrite formation.

In contrast, compared with dendrites, axons and axon terminals showed a lower Drp1 expression level. Considering that synaptic vesicle trafficking leads to the largest metabolic burden in presynaptic terminals, and this huge energy demand is pivotal in neuronal transmission \[[@CR35]\], we provide two possible speculations. First, our experimental samples and data must be further analyzed. Second, neurons might contain some other molecules that could also induce the mitochondrial fission process in other neuronal compartments. Although many proteins participate in the mitochondrial fission mechanism, including Fis1 (fission protein 1), Mff (mitochondria fission factor) and MiD49, MiD51 (mitochondria dynamics proteins of 49 and 51 kDa), Drp1 is still known as the crucial factor \[[@CR36]\]. Therefore, further investigation is still needed to reveal other potential fission factors.

Moreover, the difference in Drp1 protein and mRNA expression has further confirmed this speculation. As the vital factor in regulating the mitochondrial fission process, Drp1 should be expressed in all cells. However, as shown in Fig. [5](#Fig5){ref-type="fig"}, Drp1 protein and mRNA expression differ in the same region, and no Drp1 expression was detected in some neurons, which might suggest that some other molecules could also regulate mitochondrial dynamics. Further observations are still needed.

The heterogeneous distribution of Drp1 may contribute to the occurrence and development of neurological diseases {#Sec15}
----------------------------------------------------------------------------------------------------------------

As we discussed above, mitochondrial dysfunction is involved in the occurrence and development of neurologic disease \[[@CR37]\]. Drp1 mutation promotes mitochondrial dysfunction \[[@CR38]\]. A large number of studies have also demonstrated that GABA is related to the development of neurological diseases.

GABA is the major inhibitory neurotransmitter in the CNS. It has been confirmed that dysfunction of GABA metabolism or GABAergic inhibitory neurons is associated with many neurological diseases, including Huntington's disease, Alzheimer's disease, anxiety, panic disorder and epilepsy \[[@CR23], [@CR24]\]. However, whether Drp1 directly affects these diseases through GABAergic inhibitory neurons is still unclear.

In the process of mapping the Drp1 distribution in the brain and spinal cord, we found a heterogeneous expression pattern of Drp1 in some inhibitory neurons. Figure [2](#Fig2){ref-type="fig"}.B shows that Drp1 was expressed in neurites of the mo layer in the cerebellar cortex. The neurons in this layer have important inhibitory effects \[[@CR39]\]. In addition, Drp1 is also expressed in the second layer of the cerebral cortex, which is the external granular layer \[[@CR40]\]. The difference in Drp1 protein expression in the cerebral cortex may be related to the diverse cell types in each layer. The second layer contains a large number of granular cells, the majority of which are GABAergic inhibitory neurons \[[@CR41]\].

Therefore, we further analyzed Drp1 expression in GABAergic neurons by utilizing GAD67-GFP knock-in mice. The results showed that the Drp1 distribution was concentrated in GABAergic inhibitory neurons. This heterogeneous Drp1 distribution among different kinds of neurons may contribute to the occurrence and development of neurological diseases.

As we discussed in the Introduction, some molecules have been found that target Drp1, including P110, mdivi-1 and OND. However, the impact of these molecules on the human body and their potential use in the clinic requires further study. Therefore, the heterogeneous distribution of Drp1 in GABAergic neurons may allow targeted treatment guidance for GABA-related diseases.

Drp1 expression in human malignant glioma further demonstrates the significance of Drp1 in cells {#Sec16}
------------------------------------------------------------------------------------------------

Based on the above results, we concluded that Drp1 was widely but heterogeneously distributed in the central nervous system, which firmly supported the importance of this molecule. However, in the central nervous system, glial cells also contribute to the regulation of normal brain function. In Fig. [6](#Fig6){ref-type="fig"}, together with neurons, we observed low levels of Drp1 expression that other part of the nervous system. As stated above, we speculated that the other regions expressing Drp1 were likely to be glial cells.

Therefore, we further analyzed Drp1 expression in human malignant glioma tissue. Compared with the mean Drp1 fluorescence intensity in every grade, we observed an increasing Drp1 fluorescence intensity trend from grade I-III. For grade IV, the mean Drp1 fluorescence intensity was significantly reduced. The highest fluorescence intensity in the moderate malignancy indicated that the changes in mitochondrial dynamics had reached a maximum. During the process of glioma growth, some cells were found to be far from the vasculature and lacked nutrients. Under this circumstance of energetic stress, Drp1 upregulation could benefit the maintenance of the stem cell population and activity \[[@CR18]\]. In grade IV, most of the normal tissue was destroyed, so the fluorescence intensity was significantly reduced. Such changes in expression have also been observed in other malignant tumors \[[@CR42], [@CR43]\].

Thus, the expression of Drp1 in human malignant glioma further demonstrated its significance in cells, and it might provide guidance that changes in Drp1 could serve as an early indicator of malignant diseases.

Inhibition of Drp1 represent a novel target for neurological diseases treatment {#Sec17}
-------------------------------------------------------------------------------

When the mitochondrion is going to divide, Drp1 will translocate from the cytoplasm to the mitochondrial outer membrane with the help of receptors and adapters \[[@CR44]\], and assemble into ring-like structures on the mitochondrial outer membrane, leading to mitochondrial fission \[[@CR45], [@CR46]\]. When Drp1 is translocated abnormally to the mitochondrial membrane, mitochondrial dynamic homeostasis regulated by Drp1 will be disrupted, leading to changes in mitochondrial morphology \[[@CR17]\]. Therefore, inhibiting the Drp1 harbored in neurons under pathological state may represent a novel target in the treatment of neurological diseases \[[@CR47]\].

For treatment, we summarize three molecules that can inhibit Drp1. P110 can effectively inhibit the translocation of Drp1 from the cytoplasm to mitochondria, and inhibit the binding of Drp1 to Fis1, thus inhibiting mitochondrial division \[[@CR17]\]. Kanda et al. observed a significant increase in Drp1 in the neuropathic pain model. Further study demonstrated that intrathecal Drp1 antisense ODN (oligodeoxynucleotide) could decrease spinal Drp1 expression \[[@CR48]\]. Additionally, the mdivi-1 is another Drp1 inhibitor. Luiz F also revealed that mdivi-1 could attenuate the neuron pathologic changes \[[@CR16]\].

There is currently still no superior method for the prevention of neurological diseases, such as AD, HD and glioma. Additionally, diagnosis of the disease often lags behind its development. Therefore, the development of new target drugs is urgently needed. It is clear that P110, mdivi-1 \[[@CR49], [@CR50]\] and OND can effectively inhibit Drp1 translocation from the cytoplasm to mitochondria. However, the impact of the abovementioned molecules on the human body and whether they can be efficiently and conveniently applied in the clinic require further study.

The present study can be improved in terms of several features. It is much better to use Drp1 knockout mice in investigations of the distribution of Drp1. Moreover, the phosphorylation status of Drp1 is essential for its interaction with Mff, and it plays a vital role in regulating mitochondrial dynamics; however, the phosphorylation status of Drp1 was not observed herein. We will examine this phenomenon in our subsequent research.

In the present study, we observed the distribution of Drp1 in the mouse CNS and found that it was widely, yet heterogeneously, distributed in the central nervous system. The heterogeneous distribution of Drp1 may be involved in the occurrence and development of neurological diseases. Moreover, we summarized three targeted molecules for treatment. We hope that this research on the relationship between Drp1 and mitochondria in neurons may facilitate molecular therapy and provide clinical guidance for neurological disease treatment. As the vital factor in mitochondrial dynamics, future studies are still needed to examine the distribution and translocation of Drp1 beyond the pathological changes.

Materials and methods {#Sec18}
=====================

Animals {#Sec19}
-------

Adult male C57BL/6 mice and GAD67-GFP knock-in mice (Center of Lab Animals, Fourth Military Medical University, Xi'an, China), weighed 25--30 g. In GAD67-GFP transgenic mice, GABAergic neurons are specifically labeled with GFP fluorescence, which will emit neurons spontaneous fluorescence under the confocal microscope. The generation and characterization of the GAD67-GFP knock-in mice has been described in our previous research \[[@CR25], [@CR27], [@CR51]\].

Experimental mice were housed and treated in strict accordance with the Rules for Animal Care \[[@CR52]\] and Use for Research and Education of Fourth Military Medical University.

Experimental procedure {#Sec20}
----------------------

### Mouse stereotaxic brain atlas {#Sec21}

Brain figures were checked with *The Allen Mouse Brain Atlas* \[[@CR21], [@CR53]\] and *The Mouse Brain in Stereotaxic Coordinates, 2nd ed* \[[@CR54]\]. Spinal cord figures were checked with *Neuroanatomy: An Illustrated Colour Text, 5th ed* \[[@CR55]\]. All figures were prepared using Adobe Photoshop 7.0.

### Intrathecal Mito-red loading {#Sec22}

In order to explore the exact Drp1 distribution on mitochondria, intrathecal Mito-Red loading was utilized to visualize mitochondrial morphology.

The characterization of MitoTracker® has been described in our previous research \[[@CR15]\]. Mito-Red (MitoTracker® Deep Red FM, Invitrogen, USA) was injected intrathecally. Mito-Red was qualified to concentration of 100 nM dissolving in 1:1 mixture of DMSO (dimethylsulfoxide). 5 μl solution was injected into subarchnoid space from a small hole on L3 vertebral lamina using a Hamilton syringe attached to 10-gauge needle. Control groups were injected with 5 μl saline using the same methods.

After 4 days, mice were perfused with 0.01 M phosphate-buffered saline (PBS; pH 7.4) and 4% formaldehyde in PBS successively after anesthesia. Brains were removed into 30% sucrose solution for tissue dehydration. After dehydration, brains were sliced into 30um using freezing microtome (CM1950, Leica). Incubation of Drp1 and fluorescence developing were same as immunofluorescence staining.

### Immunofluorescence staining {#Sec23}

In order to map the Drp1 protein expression in central nervous system, immunofluorescence staining was utilized in three kinds of animals, including normal adult C57BL/6 mice, intrathecal injection of Mito-Red mice and GAD67- GFP mice. Light should be avoided during Mito-Red mice operation, other operations were same to C57BL/6 mice and GAD67- GFP mice. Mito-Red mice and GAD67- GFP mice will emit spontaneous fluorescence under confocal microscope. Therefore, slices of these two groups only need single label of anti-Drp1 antibody incubation.

Mice were perfused with 0.01 M PBS and 4% formaldehyde in PBS successively after anesthesia. Brains and spinal cord were removed into 30% sucrose solution for tissue dehydration. After dehydration, brains were sliced into 30um using freezing microtome (CM1950, Leica, Germany). To determine the distribution and localization of Drp1, slices were transferred to PBS and then 10% calf serum for 30 min. Then slices were incubated with 1:250 diluted anti-Drp1antibody (ab184247, Abcam, UK) at 4 °C overnight. In order to avoid false positive results, Tempol (ROS scavenger) was utilized to treat the tissue. After anti-Drp1antibody incubation, the tissue was treated in Tempol (380 nmol/5 μ L) solution for 1 h. Then slices were incubated with 1:500 diluted secondary antibody (goat anti-rabbit IgG; Sigma, St. Louis, MO, USA) for 2 h. Slides were rinsed triple times for 15 min with 0.01 M PBS after incubation. No signal was detected when the primary or secondary antibody was omitted. Images were recorded using confocal microscopy (FV1000, Olympus, Japan) connected to an inverted microscope.

### FISH (fluorescence in situ hybridization) {#Sec24}

In order to observe the Drp1 mRNA distribution in central nervous system, fluorescence in situ hybridization was utilized. Drp1 gene primer was designed and used in our previous research \[[@CR56]\].

Drp1 gene upstream primer 5′-3′: GCTCAGTGCTGGAAAGCCTA; downstream primer 5′-3′: GATGGATTGGCTCAGGGCTT, amplification length: 297 bp.

Construction of probe plasmids: cDNA of C57BL/6 mice were amplified by PCR with primers; gel was used to recycle the PCR products; the products were linked to carriers at room temperature with T7 and SP6 promoters at both ends (Roche, Switzerland); the plasmids were transformed into E.coli DH5alpha and cultured; the probe plasmids were extracted by Plasmid Extraction Kit (Tiangen, China) and then were sequenced.

Probe preparation: using the sequenced plasmid as template, PCR amplification was carried out with T7 and SP6 specific primers, PCR products were recycled by Omega Gel Recycle Kit (Omega, USA), probe was transcribed into cRNA in vitro by T7-RNA polymerase/ SP6-RNA polymerase.

Mice were anaesthetized with 25% uratan solution (6 ml/kg, intraperitoneal injection), rinsed the blood from right atrial appendage with 30 ml (0.01 M DEPC-PBS), then rinsed the blood with 4% paraformaldehyde 100 ml. After perfusion, the mice brain and lumbar spinal cord (lumbar enlargement) were removed completely, and were put in 4% paraformaldehyde fixative solution in the refrigerator at 4 °C for 24 h. Then slices were removed in 30% DEPC sucrose solution in 4 °C refrigerator for 48 h. Coronal sections were cut by Leica CM1950 (Germany). Brain slices and spinal cord slices were 30 and 25um thick, respectively. Slices were treated in 0.1 M DEPC-PB containing 2% H2O2 for 10 min, 0.1 M DEPC-PB containing 0.3% Triton X-100 for 20 min and acetylation solution for 10 min at room temperature, respectively. Slices were incubated in hybridization buffer at 58 °C for 1 h.Drp1 cRNA probe was added to the above-mentioned hybridization buffer (final concentration: 1 μg/ml) and incubated in the hybridization oven at 58 °C for 20--24 h. Rinsed slices and treated it with RNA enzyme solution for 5 min at room temperature, 2 \* SSC and 0.2 x SSC (diluted by 20 \* SSC, with 2% NLS) was used to rinse the slices twice, 20 min each time, 37 °C, respectively. Slices were incubated with antibody POD-anti-DIG (1:1500) for whole night, β-D-Glucose (1:100) for 30 min, FITC-avindin (1:500), for 3 h and DAPI (1:1000) for 15 min at room temperature. After incubation, the slices were observed and photographed by laser confocal microscopy (FV1000, Olympus, Japan).

### Western blotting and analysis {#Sec25}

In order to preliminarily explore whether the Drp1 protein has regional specific distribution characteristics, western blot was used to detect the protein in mice central nervous system.

10% SDS--polyacry-lamide gel electrophoresis (SDS-PAGE) was prepared \[[@CR57]\]. Equal amounts of protein (30 μg) were electrophoresed on 10% SDS--polyacrylamide gels and transferred 2 h onto PVDF-membrane, which were incubated with anti-Drp1 antibody (1:1500, Abcam, UK) and secondary antibody (horse-radish peroxidase-conjugated anti-rabbit IgG from donkey, Amersham, Biosciences, Piscataway, NJ, USA) \[[@CR57]\]. Immunoblots were developed using ECL kit (K-12045-D10; Advansta, USA) and BIO-RAD ChemiDoc MP lighting machine, results were quantified by computerized scanning densitometry and analyzed by Image J software.

### IEM (Immunoelectron microscopy) {#Sec26}

In order to explore Drp1 localization on mitochondria in subcellular level, we utilized immunoelectron microscopy for further observation. IEM contains different labeling methods. In this experiment, immune colloidal gold technique was utilized to label Drp1. The colloidal gold was tracer, and could be polymerized into gold particles of specific size under the action of reducing agent, and further combined with positively charged protein molecules in the weak alkali environment \[[@CR28], [@CR29]\].

The shooting area was PAG. After perfusion, the brain was removed immediately and was cut into small pieces (PAG area). The tissue was fixed with 4% paraformaldehyde fixative of 15% saturated picric acid, and then was sliced into 50 um thick. Then slices were used vibration microtome (DTK-1000, D.S.K., Japan) to obtain coronary section. And slices were treated into frozen section by liquid nitrogen, and were incubated with 20% donkey serum (diluted by 0.05 M TBS) for 30 min, rabbit anti-Drp1 antibody (1:100, Abcam, UK), 2% donkey blood were added afterwards for 24 h' incubation. After primary incubation, sheep anti-rabbit (1:100, Nanoprobes, USA) labeled with immune NG (nanogold particles) and 2% donkey serum (0.05 M TBS diluted) were added for further incubation overnight at room temperature. Silver-enhanced reaction: HQ Sliver Kit (Nanoprobes, USA) treatment for 7--14 min, then dripped into Ainitator, B moherntor, C activator reagent one drop, respectively. After 7 min reaction, the slices were poured into distilled water to stop the reaction. Then, slices were incubated with 1% osmic acid solution for 35 min, then treated 70% alcohol and 1% uranyl acetate for 40 min. Then slices were removed into 70% \~ 100% gradient alcohol and propylene oxide for dehydration. Slices were polymerized in the embedding agent overnight. After stained with lead citrate, slices could be observed and photographed under electron microscope (JEM1400, Tokyo, Japan).

The criteria for distinguishing different parts are as follows: 1. Soma: Soma contains less heterochromatin, the color is light, and the nucleolus is large and obvious.The cytoplasm contains rough endoplasmic reticulum, free ribosome, Golgi complex, neurofilament and microtubule; 2. Mitochondrion: Mitochondrion is the organelle surrounded by two layers of membrane, which is oval or long strip, and its length changes greatly. 3. Dendrite: Dendrites contain Nissl body, mitochondria, Golgi complex, smooth endoplasmic reticulum, neurofilament and microtubule. Clusters of ribosomes often appear with irregular outline, prominent ratchet like accessory structures including hypertrophic mitochondria, microtubules, and post prominent specialized structures. 4. Axons: The axon structure is thin, smooth and without spines. Axons are usually separated from the cell body. Under the electron microscope, the main cell components in axons are free ribosome, mitochondria, neurofilament and microtubule. With the extension of axons, rough endoplasmic reticulum and ribosome gradually decreased or even disappeared. Some axons are surrounded by myelin sheath. 5. Axon terminals: The axon terminals are spherical, expanded and thickened to form presynaptic membrane. Synaptic vesicles and several mitochondria could be found in axon terminal.

Glioma tissues screening and staining {#Sec27}
-------------------------------------

### Glioma tissues screening {#Sec28}

Patient glioma tissues were provided by Xijing hospital. All patients provided written informed consent before glioma tissues recruitment. After screening, 3 cases of hairy cell astrocytoma, 6 cases of diffuse astrocytoma, 6 cases of anaplastic astrocytoma, 13 cases of glioblastoma, 13 cases of oligodendrocytoma, 13 cases of anaplastic oligodendrocytoma and 6 cases of paracancerous tissue were included in this study.

### HE staining {#Sec29}

HE staining was conducted according toroutine protocols. 4-μm sections were obtained from each paraffin block utilizing pathological microtome (Leica RM2235, Germany). After deparaffinization and rehydration, sections were stained with hematoxylin solution (Solarbio, G1080, China) for 5 mins, stained with eosin (Solarbio, G1100--100, China) for 3 mins and re-immersed in alcohol and xylene. The mounted slides were then examined and photographed using inverted microscope (NikonCI-S, Japan) and imaging system(NikonDS-U3, Japan).

### Glioma staining {#Sec30}

The slides of glioma cells were taken out from PBS and rinsed in PBS for 3 times at room temperature, 10 min/time; 10% calf serum was used for 2 h incubation; slides were incubated in anti-rabbit-anti-Drp1 (Abcam, ab184247, 1:1000, UK) overnight in a wet and dark box at room temperature; rinsed slices in PBS at room temperature for 3 times, 10 min/time in next day; incubated the slices in anti-a488-anti-rabbit (Abbkine, 1:500, USA) for 2 h; rinsed slices 3 times in PBS at room temperature, 10 min/time; sealed slices with fluorescent sealing agent and photographed under confocal microscope (FV1000, Olympus, Japan).

Statistical analysis {#Sec31}
--------------------

Data are presented as the mean ± SEM (standard error of the mean). One-way repeated-measures ANOVA was used for the analysis of differences between the experimental groups. Kruskal-Wallis test was used to confirm the Drp1 distribution differences between dendrites, axons, axon terminals and somas under IEM. *p* \< 0.05 was considered statistically significant. Data are analyzed through SPSS 21.0 software.
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:   Facial motor nucleus

RSPd

:   Retrosplenial area, dorsal part

RSPv

:   Retrosplenial area, ventral part

PTLp

:   Posterior parietal association areas

AUD

:   Auditory areas

TEa

:   Temporal association areas

BLA

:   Basolateral amygdalar nucleus

PIR

:   Piriform area

alv

:   Alveus

df

:   Dorsal fornix

PO

:   Posterior complex of the thalamus

VPM

:   Ventral posteromedial nucleus of the thalamus

VPL

:   Ventral posterolateral nucleus of the thalamus

fr

:   Fasciculus retroflexus

PF

:   Parafascicular nucleus

IC

:   Inferior colliculus

AQ

:   Cerebral aqueduct

DR

:   Dorsal nucleus raphe

MRN

:   Midbrain reticular nucleus

V4

:   Fourth ventricle

PCG

:   Pontine central gray

scp

:   Superior cerebelar peduncles

V4r

:   Lateral recess

icp

:   Inferior cerebellar peduncle

FL

:   Flocculus

SPVO

:   Spinal nucleus of the trigeminal, oral part

sptV

:   Spinal tract of the trigeminal nerve

VCO

:   Ventral cochlear nucleus

DCO

:   Dorsal cochlear nucleus

IRN

:   Intermediate reticular nucleus

PARN

:   Parvicellular reticular nucleus

sctv

:   Ventral spinocerebellar tract

rust

:   Rubrospinal tract

SPVI

:   Spinal nucleus of the trigeminal, interpolar part

IP

:   Interposed nucleus

SPIV

:   Spinal vestibular nucleus

MDRNd

:   Medullary reticular nucleus, dorsal part

ECU

:   External cuneate nucleus

NTS

:   Nucleus of solitary tract

PAS

:   Parasolitary nucleus

NeuN

:   Neuronal nuclear antigen

NG

:   Nanogold particles

ODN

:   Oligodeoxynucleotide

LSD

:   Least significant difference
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